Shantou Institute of Ultrasonic Instrument
301602
Hubei Sinophorus Electronic Materials
688545
Pansoft
300996
4
Jiayu Holding
300117
5
Wuxi Taclink Optoelectronics Technology
688205
CN Stock MarketDetailed Quotes
002581 Shandong Sinobioway Biomedicine
- 10.21
- -0.04-0.39%
Market Closed Jan 22 15:00 CST
6.74BMarket Cap-19.37P/E (TTM)
10.27High10.06Low44.37KlotVolume10.24Open10.25Pre Close45.04MTurnover1.11%Turnover RatioLossP/E (Static)659.74MShares14.4352wk High3.22P/B4.09BFloat Cap7.7952wk Low11.28Limit Up400.79MShs Float71.85Historical High9.23Limit Down2.05%Amplitude4.39Historical Low--Dividend TTM10.15Avg Price19.56KlotAsk--Div YieldTTM100Lot Size24.24KlotBid
Shandong Sinobioway Biomedicine News
Unnamed Medicine: Announcement of Resolutions of the 32nd Meeting of the Fifth Board of Directors
Unnamed Medicine: Announcement on the Proposed Signing of the “Technical Service Agreement for Drug Clinical Trials”
Unnamed Pharmaceuticals: Announcement on capital increase to wholly-owned subsidiary
Unnamed Pharmaceuticals: Announcement on Granting Stock Options to Incentive Recipients of the Company\'s 2024 Stock Options Incentive Plan
Unnamed Pharmaceuticals: Supervisory Board\'s Review Opinions on the List of Incentive Recipients Granted by the Company\'s 2024 Stock Option Incentive Plan
Unnamed Medicine: Announcement of Resolutions of the 31st Meeting of the Fifth Board of Directors
Unnamed Medicine: Legal Opinion of Zhejiang Tianzu (Shenzhen) Law Firm on the awarding of the 2024 Stock Option Incentive Plan for Shandong Weiming Biomedical Co., Ltd.
Unnamed Medicine: Announcement of Resolutions of the 21st Meeting of the Fifth Board of Supervisors
Unnamed Pharmaceuticals: Announcement of Resolutions of the 2024 Fourth Extraordinary General Meeting of Shareholders
Unnamed Pharmaceuticals: Self-inspection Report on the 2024 Stock Options Incentive Plan: Insider Information Insiders and Incentive Targets to Trade Company Shares
Unnamed Medicine: Legal Opinion of Zhejiang Tianze (Shenzhen) Law Firm on the 2024 Fourth Extraordinary General Meeting of Shareholders of Unnamed Medicine
Unnamed Pharmaceuticals: Explanation and Verification Opinions of the Supervisory Board on the Publication of the Company\'s 2024 Stock Option Incentive Plan Incentive List
Unnamed Pharmaceuticals: Announcement on the progress of the transfer of shares in participating companies through public listing
Unnamed Pharmaceuticals: Announcement on the Change of Chief Financial Officer
Unnamed Medicine: Announcement of Resolutions of the 30th Meeting of the Fifth Board of Directors
Unnamed Pharmaceuticals: An indicative announcement on the adoption of an autonomous exercise model during the first exercise period of the 2023 Stock Options Incentive Plan
Unnamed Pharmaceuticals: Shandong Weiming Biomedical Co., Ltd. 2024 Stock Option Incentive Plan Implementation Assessment Measures
Unnamed Pharmaceutical: Notice on requesting the shareholders\' meeting to authorize the board of directors to handle matters relating to the company\'s 2024 stock option incentive plan
Unnamed Medicine: Announcement on the By-election of Independent Directors of the 5th Board of Directors and the Adjustment of Members of the Special Committee of the Board
Unnamed Medicine: Announcement of Resolutions of the 20th Meeting of the Fifth Board of Supervisors